Today's Date
Tregs and IL-2 in Type 1 Diabetes
(
TILT
)
ITN Protocol #:
ITN827AI
Branded Name:
TILT
Treatment Protocol #:
Therapeutic Area:
Type 1 Diabetes
Current Status:
Complete
Summary:
A Phase 1 Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy with Interleukin-2 for the Treatment of Type 1 Diabetes
Clinical Operations Manager
ITN Biostat
ITN Clinical Trial Physician
Study Personnel:
